Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses

摘要

Platelet-activating factor (PAF) is a lipid-derived mediator that has been implicated in the pathophysi- ology of airway inflammation in asthma. Lts actions include chemotaxis and activation of inflamma- tory cells, particularly eosinophils. Inhaled PAF causes bronchoconstriction and increased airway re- sponsiveness in human subjects. However, PAF antagonists have so far failed to show benefits in allergen challenge or in the treatment of chronic asthma. SR274A is a novel PAF antagonist with in- creased potency compared with previously tested compounds.